Rodolphe Clerval, Coave Therapeutics
On a mission to treat patients not covered by Luxturna, Horama refuels with a Series B expansion and a new name
About four years after closing its Series B round the first time, Horama is adding another $25.1 million to its coffers for its work on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
